- On 27 June 2026, Repligen Corporation was removed from multiple Russell growth benchmarks, including the Russell 1000 Growth and Russell 3000 Growth Indexes, marking a broad shift in its benchmark index representation.
- This widespread index exclusion can influence how passive funds and benchmark-aware active managers hold or trade the stock, potentially altering liquidity patterns and the shareholder base.
- Next, we’ll examine how Repligen’s removal from several Russell growth benchmarks may affect its existing investment narrative and risk-reward profile.
Rare earth metals are the new gold rush. Find out which 31 stocks are leading the charge.
Repligen Investment Narrative Recap
To own Repligen today, you need to believe its bioprocessing tools can keep gaining share with large pharma and CDMOs, even as smaller biotech demand and modality exposure introduce uncertainty. The broad removal from Russell growth indexes may influence short term trading flows and liquidity, but it does not directly change the key near term drivers around order trends, margin execution, or the risk that funding constrained emerging biotech customers continue to order cautiously.
The recent opening of the Repligen Training & Innovation Center in Breda, Netherlands is especially relevant here, as it underscores the company’s focus on deepening customer engagement and adoption of its OPUS chromatography and filtration technologies. While this expansion supports the long term use case for Repligen’s platform, the benefit will still depend on how quickly customers ramp projects and spending, particularly in areas where funding and regulatory conditions remain uncertain.
Yet behind the index changes, investors should be aware of how concentrated exposure to specific modalities and funding sensitive customers could still...
Read the full narrative on Repligen (it's free!)
Repligen's narrative projects $1.1 billion revenue and $155.4 million earnings by 2029.
Uncover how Repligen's forecasts yield a $176.11 fair value, a 26% upside to its current price.
Exploring Other Perspectives
Some of the lowest ranked analysts already saw more risk here, even before the Russell removals, assuming revenue of about US$1.1 billion and earnings of roughly US$122 million by 2029, and warning that customer concentration and macro pressures could hit those goals harder than the consensus expects.
Explore 3 other fair value estimates on Repligen - why the stock might be worth just $142.00!
Reach Your Own Conclusion
Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.
- A great starting point for your Repligen research is our analysis highlighting 4 key rewards and 1 important warning sign that could impact your investment decision.
- Our free Repligen research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Repligen's overall financial health at a glance.
Ready For A Different Approach?
Every day counts. These free picks are already gaining attention. See them before the crowd does:
- Find 45 companies with promising cash flow potential yet trading below their fair value.
- Invest in the nuclear renaissance through our list of 89 elite nuclear energy infrastructure plays powering the global AI revolution.
- AI is about to change healthcare. These 40 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com